



# **NATIONAL CANCER RESEARCH INSTITUTE (NCRI) CLINICAL STUDIES GROUPS**

---

## **Remit of NCRI Clinical Studies Groups**

**Version 5.0**

**October 2009**

Each NCRI Clinical Studies Group has a UK-wide remit to:

1. be responsible for its trials portfolio,
2. propose new trials and other well-designed studies,
3. consider trials proposed by others,
4. consider international and commercial trials for inclusion in the portfolio,
5. consider studies in health service research,
6. be responsible for its subgroups,
7. work with other CS(D)Gs as appropriate,
8. receive inputs
  - from ECMCs and early clinical trials groups
  - from NCRN evidence reviews and economic reviews
9. submit applications for trials approval,
10. provide tumour specific or task specific advice, as required, to the NCRN Operational Steering Group or NCRI,
11. undergo peer review of their overall portfolio 3-yearly,
12. have an overview of what is happening in paediatric subgroups or subgroups into which paediatric trials have been included/subsumed in other CS(D)Gs.<sup>1</sup>
13. To foster translational research (TR) in the trial portfolio that would enhance the potential for stratified medicine.

---

<sup>1</sup> Children's Cancer & Leukaemia Clinical Studies Group only.